OMEROS CORP OMER
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-9.19
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$3.4M | — | -$116.2M | -$121.2M |
| 2024 | — | -$156.8M | — | -$149.0M | -$182.6M |
| 2023 | — | -$117.8M | — | $74.3M | -$25.0M |
| 2022 | — | $47.4M | — | -$86.6M | $85.7M |
| 2021 | — | $194.2M | — | -$110.0M | $23.8M |
| 2020 | $73.8M | -$138.1M | — | -$100.4M | -$120.8M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.19 (distress)
- Working capital / assets 0.423
- Retained earnings / assets -2.806
- EBIT / assets -0.377
- Equity / liabilities -0.271
Source: SEC EDGAR filings · CIK 0001285819 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.